Abstract: During the last two decades, there has been an alarming worldwide increase of resistance to antibiotics of bacterial pathogens responsible for community-acquired infections. This dramatic evolution is generally attributed to the extensive use of antibiotics and the selective pressure on the bacterial strains. To decrease antibiotics resistance in the community, several approaches should be considered through: reducing unnecessary antibiotic prescriptions: inappropriate antibiotic treatments are becoming a major issue; however, few studies have shown a decrease of antibiotic resistance following a reduction of antibiotic use in the community; decreasing the prescriptions of the more selective antibiotic compounds for some bacterial species, eg macrolides and group A streptococcus (GAS), trimethoprim-sulfamethoxazole and pneumococcus; using an optimal dosage and duration of antibiotic regimens chosen; some studies have suggested that low dosage and long treatment duration could promote antibiotic resistance; and implementing the pneumococcal conjugate vaccines; several studies have shown a decline in the proportion of penicillin nonsusceptible Streptococcus pneumoniae isolated from invasive pneumococcal diseases or nasopharyngeal flora. The combination of these approaches, particularly the reduction of antibiotic use and pneumococcal immunization, could be synergistic.
T he prevalence of antibacterial resistance among community-acquired pathogens has increased dramatically over the last 2 decades. 1, 2 The clinical impact of antibacterial resistance is evident from an increasing number of clinical failures reports. [3] [4] [5] This antibiotic resistance phenomenon involves not only respiratory pathogens as Streptococcus pneumoniae, group A streptococcus (GAS) or Haemophilus influenzae but also agents responsible for urinary, digestive, or cutaneous infections as Escherichia coli, Shigella sonnei or Staphylococcus aureus. 1 Furthermore, bacterial resistance to multiple antibacterial agents is rapidly becoming a worldwide problem as it may limit treatment options. 1 This dramatic evolution of resistance should lead to very serious problems in a few years, particularly because most big pharmaceutical companies have stopped the research of new compounds, tying in with the problems created by antibiotic resistance. The main reasons for the uninterest of pharmaceutical companies are that the market becomes unattractive due to the prospective restriction of antibiotic use, the relatively few patients involved and the shortened treatment durations.
To reduce this worrying trend, I suggest several approaches: reducing unnecessary antibiotic prescriptions, prescribing the less selective antibiotic regimens, and, finally, promoting implementation of vaccines, particularly pneumococcal conjugate vaccines (PCV).
REDUCING UNNECESSARY ANTIBIOTIC PRESCRIPTIONS
Several studies have shown higher rates of antibiotic resistance in high-antibiotic-consuming countries. 6 On an individual level, antibiotic use has been linked to an increased risk of harboring or becoming infected with antibiotic-resistant bacteria. [7] [8] [9] Misuse of antibiotics for viral upper respiratory tract infections has been well documented, with high prescribing rates. 10, 11 In many countries where the consumption is high, the question is not if we have to limit the antibiotic prescriptions but how, and if the reduction of antibiotic use can decrease the antibiotic resistance. Although examples of a correlation between resistance and antibiotic usage have been reported, not all studies have shown sustained decrease in pneumococcal resistance with declining antibiotic prescriptions. 12, 13 To reduce antibiotic prescriptions and, consequently, antibiotic consumption, multifaceted educational programs to promote more prudent use of antibiotics must be implemented, involving physicians and other health care workers and also consumers of care (patients, parents). [12] [13] [14] In fact, it has been demonstrated that, on one hand, parental pressure for an antibiotic has been associated with antibiotic prescribing, and, on the other hand, that programs involving only parental educational intervention have little or no effect. 15 Programs for physicians and parents have to include two key points:
1. tools to help physicians to reduce diagnostic uncertainty 2. reassurance that reduction of antibiotic use is not linked to an increase of severe bacterial diseases Tools to Reduce the Diagnostic Uncertainty. The diagnostic uncertainty increases the prescriptions of antibiotic treat-ments. 16 Tools to reduce the diagnostic uncertainty include the establishment of national or local guidelines, their dispersion, and an improved training of primary care physicians, particularly for general practitioners. Furthermore, the implementation of rapid diagnostic tests could help. In many countries, most patients suffering from pharyngitis receive antibiotic treatments only on the basis of clinical signs and symptoms. Most pharyngitis is caused by viruses, and GAS is the only cause that currently merits antimicrobial treatment. The main consideration in managing pharyngitis is to determine who has GAS pharyngitis to institute appropriate antibiotic therapy and who does not have strep infection and therefore does not need antibiotic treatment. Scoring systems can reduce antibiotic usage but are insufficiently sensitive and specific. If throat culture is the gold standard, rapid antigen tests (RAT) have been improved. In the "real world," analysis of office performance of throat cultures and RAT suggests little difference in accuracy. In fact, in the office or emergency setting, there may be little benefit to confirming negative RAT with throat cultures in areas with little or no acute rheumatic fever. In Slovenia and France, the implementation of RAT in the last years has been followed by significant reduction of antibiotic use. 17, 18 In Slovenia, there was a negative correlation between the number of RAT and antibiotic use (r ϭ Ϫ0.68).
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Other rapid diagnostic tests could have a positive impact on the reduction of antibiotic use. Because of increasing pressure to use antibiotics only for proven bacterial diseases, diagnosis of viral illness becomes more paramount. Several studies have shown that patients with documented influenza infection have fewer antibiotics administered, thus reducing indiscriminate antibiotic use in proven viral illness. 19 -21 Bonner et al 21 recently have shown that the use of rapid diagnostic test kits for influenza could lead to a clear reduction of antibiotic use in the pediatric emergency setting.
Furthermore, in Slovenia, there was a negative correlation between the number of C-reactive protein tests and antibiotic consumption (r ϭ Ϫ0.73).
Reduction of Antibiotic Use and Alleged Increase of Severe Bacterial Diseases. If some data have suggested an association between reduced prescribing and an increased incidence of rare complications of bacterial infection, 22 ,23 2 studies, published this last year, provide confirmation. 17, 24 The first one, by Cizman et al 17 in Slovenia, has shown that the reduction of antibiotic use during the last 5 years has not induced an increasing rate of mastoiditis. The second one, by Sharland et al, 24 has reported, over the past decade in England, that antibiotics' use has halved and that this reduction has not been associated with an increase in admission to the hospital for peritonsillar abscess or rheumatic fever. In the same study, data on mastoiditis and simple mastoidectomy are conflicting: apparent increase in hospital events and reduction in general practice.
USE OF LESS SELECTIVE ANTIBIOTIC REGIMENS
Antibiotic Compounds. Higher potential to promote carriage of antibiotic resistant Streptococcus pneumoniae has been suggested for macrolides (particularly azithromycin), trimethoprim-sulfamethoxazole and oral cephalosporins, compared with penicillins. 25, 26 Significant association has been also suggested between temporal and regional erythromycin resistance in S pyogenes and consumption of macrolides. 27, 28 However, the ability of any drug to promote carriage of resistant strains depends on the prevalence of resistance in the community: when the prevalence of resistance in the community is absent or low, it is difficult to demonstrate an increase of resistance in individuals who receive a drug; when the levels of resistance are intermediate, selection-pressure phenomenon becomes more easily apparent; ultimately, the effect can be masked in areas where resistance is high. Optimal Dosage and Duration of Antibiotic Regimens. Three studies, at least, have shown that low dosage and/or long treatment duration increase the risk of carriage of resistant strains. Guillemot et al, 28 in a prospective observational study, have suggested that carriage of penicillin nonsusceptible pneumococci (PNSP) was associated with low daily doses of oral ␤-lactam (OR, 5.9; 95% CI, 2.1-16.7) and long (Ͼ5 days) treatment duration (OR, 3.5; 95% CI, 1.3-9.8). Schrag et al 29 in prospective randomized study comparing amoxicillin 90 mg/kg per day for 5 days and 40 mg/kg per day for 10 days have shown that the risk of PNSP carriage was lower at 1 month in the short-course, high-dose group (24%) compared with the standard-course group (32%) (P ϭ 0.03) (RR,0.77; 95% CI, 0.60 -0.97).
Our group has published a few years ago a study comparing 2 azithromycin dosages: the 20 mg/kg/d dose of azithromycin has had a better effect than the 10 mg/kg/d dose in terms of minimizing the risk of emerging resistance in the GAS. 30 Using the molecular tools restriction fragment length polymorphism and random amplified polymorphic DNA, we found 8 cases of bacteriologic treatment failure with genetically related strains that had increased azithromycin MICs after treatment with 10 mg/kg/d azithromycin. This phenomenon did not occur with the 20 mg/kg/d azithromycin for a 3-day regimen.
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VACCINATION PROGRAMS
Several vaccines may contribute to reduction of opportunities to prescribe antibiotic treatments: eg pertussis, varicella, and certainly influenza vaccine. Neuzil et al 31 have shown in Tennessee that for every 100 children, an annual average of 3 to 9 courses of antibiotics was attributable to influenza.
Furthermore, reductions of 25% in antibiotic use for influenza-associated illnesses 32 and of 41%-45% in days of antibiotic use 33 have been reported after influenza vaccination. However, the most promising are the PCVs. In fact, these vaccines can reduce the antibiotic prescriptions and have a direct effect on pneumococcal resistance. There is evidence suggesting that the use of these conjugate vaccines will reduce the need for antibiotics and the subsequent spread of antibiotic-resistant pneumococci. Dagan et al 34 have shown that PCVs reduce occurrence of respiratory infections and antibiotics' use in daycare-center attendees. Because pneumococcus is the leading cause of bacteremia in young febrile children, it should be emphasized that the risk of 35 because the vaccine-type strains represent the majority of antibiotic-resistant strains. Others studies have shown a decline in the proportion of PNSP isolated from invasive pneumococcal disease after the implementation of PCV immunization. 36 Recently, our group has shown in France that the implementation of PCV combined with a reduction in antibiotic use, in a country with a high prevalence of antibiotic-resistant pneumococci, appears to have a strong impact on the carriage of highly penicillin-resistant pneumococcus (HPRP). 37 To follow the Sp serotypes and antibiotic resistance trends after the implementation of PCV, a national prospective surveillance network was set up after September 2001. French pediatricians were recruited to carry out nasopharyngeal swabs in infants and toddlers suffering from AOM. Over the 3-year survey, 1906 patients were enrolled. The percentage of PCV-vaccinated children increased from 8.2% (first year) to 19.9% (second year) and 61.4% (third year). Antibiotic usage within 3 months before enrollment has been reduced from years 1 to 3, respectively: 51.5%, 44.5%, 40.7%. The risk for a child to carry HPRP was 4.2% (95% CI, 3.3%-5.1%) for children immunized and who had not received antibiotic treatment within 3 months before enrollment, 8.6% (95% CI, 7.4%-9.9%) for those vaccinated and who had received antibiotic treatment, 10.3% (95% CI, 8.9%-11.7%) for children not immunized and who had not received antibiotic treatment, and 16.2% (95% CI, 14.5%-17.9%) for children not vaccinated and who had received antibiotic treatment during the same period. However, pneumococci can undergo capsular serotype switching; therefore, the potential exists for a vaccine-serotype clone that is resistant to an antibiotic to switch its capsule to a nonvaccine serotype and hence evade the protective effects of PCVs. 38, 39 These observations underscore the importance of ongoing surveillance of Streptococcus pneumoniae isolates.
CONCLUSION
To reduce antibiotic resistance in the community, approaches have to be combined. Reduction of unnecessary antibiotic prescriptions, combined with the implementation of PCVs, is probably the most efficient strategy. In addition, prescription of the less selective antibiotic compounds and use of optimal dosage and duration must be recommended.
